WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999038499) METHODS AND COMPOSITIONS FOR AIDING IN SMOKING CESSATION AND FOR TREATING PAIN AND OTHER DISORDERS USING OPTICALLY PURE (-)-BUPROPION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/038499    International Application No.:    PCT/US1999/001951
Publication Date: 05.08.1999 International Filing Date: 28.01.1999
Chapter 2 Demand Filed:    23.08.1999    
IPC:
A61K 31/135 (2006.01), A61K 31/137 (2006.01)
Applicants: SEPRACOR INC. [US/US]; 111 Locke Drive Marlborough, MA 01752 (US)
Inventors: MCCULLOUGH, John, R.; (US).
RUBIN, Paul, D.; (US)
Agent: LAWRENCE, Stanton, T., III; Pennie & Edmonds LLP 1155 Avenue of the Americas New York, NY 10036 (US)
Priority Data:
60/072,932 29.01.1998 US
Title (EN) METHODS AND COMPOSITIONS FOR AIDING IN SMOKING CESSATION AND FOR TREATING PAIN AND OTHER DISORDERS USING OPTICALLY PURE (-)-BUPROPION
(FR) PROCEDES ET COMPOSITIONS DE (-)-BUPROPION OPTIQUEMENT PUR DESTINES A FACILITER LA DESACCOUTUMANCE AU TABAC ET AU TRAITEMENT DE DOULEURS ET D'AUTRES TROUBLES
Abstract: front page image
(EN)Methods and compositions are disclosed utilizing the optically pure (-)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
(FR)La présente invention concerne des procédés et des compositions de l'isomère(-) de bupropion optiquement pur, destinés à faciliter la désaccoutumance au tabac, au traitement de la dépendance à la nicotine et au tabac, et au traitement de douleurs, y compris, mais de façon non limitative, de douleurs chroniques, de neuropathies et d'algodystrophie sympathique réflexe, et d'autres troubles tels que la narcolepsie, le syndrome de fatigue chronique, la fibromyalgie, les troubles affectifs saisonniers et le syndrome prémenstruel, tout en évitant les effets indésirables associés au bupropion racémique.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)